Menu

Press Releases

Date Summary View
Toggle Summary RedHill Biopharma Increases Patient Access to Talicia® with EnvisionRx Formularies
Talicia ® is the first and only FDA-approved rifabutin-based therapy for H. pylori infection designed as a first-line option to address the high and growing resistance of H. pylori to   clarithromycin-based therapies Talicia ® is targeting an estimated two million U.S. ...
View HTML
Toggle Summary RedHill Biopharma Accelerates Phase 2/3 COVID-19 Program with Addition of Brazil and Mexico
Phase 2/3 study process initiated in Brazil and Mexico  The global Phase 2/3 study with opaganib in patients with severe COVID-19 has already been approved in the UK and Russia     Enrollment planned to be initiated this month - 270 subjects to be enrolled in up to 40 clinical sites   Potential ...
View HTML
Toggle Summary RedHill Biopharma Seeks SEC Review of Suspicious Trading Activity
TEL-AVIV, Israel and RALEIGH, N.C. , July 21, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, announced today it is seeking regulatory review by the Securities and Exchange Commission (“SEC”), and intends to ...
View HTML
Toggle Summary RedHill Biopharma Receives Approval for Phase 2/3 COVID-19 Study in Russia
Clinical Trial Application approved in Russia for the Phase 2/3 study with opaganib in severe COVID-19 patients following recent approval in the UK and similar submission in Italy -- The Phase 2/3 study aims to enroll 270 subjects in up to 40 clinical sites; enrollment planned to be initiated later ...
View HTML
Toggle Summary RedHill Biopharma to Present at the Sachs Novel Coronavirus Investment Forum
TEL-AVIV, Israel and RALEIGH, N.C. , July 01, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Mr. Gilead Raday , RedHill's Chief Operating Officer, will present the Company’s ongoing Phase 2/3 ...
View HTML
Toggle Summary RedHill Biopharma Receives Approval for COVID-19 Phase 2/3 Study with Opaganib in the UK
The Phase 2/3 multi-center, randomized, double-blind, parallel-arm, placebo-controlled study with opaganib aims to enroll 270 severe COVID-19 patients in up to 40 clinical sites across the UK , Italy , Russia and additional countries  -- In parallel, a U.S. ...
View HTML
Toggle Summary Publication of Data from Severe COVID-19 Patients Shows Substantial Benefit to Patients Treated with RedHill’s Opaganib Compared to Matched Case-Control Group
Analysis of treatment outcomes in five severe COVID-19 patients showed substantial benefit to patients treated with opaganib under compassionate use in both clinical outcomes and inflammatory markers as compared to a matched case-control group from the same hospital -- All patients in the ...
View HTML
Toggle Summary RedHill Biopharma Expands Opaganib COVID-19 Phase 2/3 Study with Clinical Trial Applications in Italy and UK
The multi-center, randomized, double-blind, parallel-arm, placebo-controlled Phase 2/3 clinical study with opaganib in 270 severe COVID-19 patients is planned to be conducted in up to 40 clinical sites across Russia , Italy , the UK and additional countries -- In parallel, a clinical study of ...
View HTML
Toggle Summary RedHill Biopharma to Present at Virtual Life Sciences Investor Forum on June 25
TEL-AVIV, Israel and RALEIGH, N.C. , June 18, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Guy Goldberg , RedHill's Chief Business Officer, will present a corporate overview at the Virtual ...
View HTML
Toggle Summary RedHill Biopharma Submits COVID-19 Clinical Trial Application for Phase 2/3 Study with Opaganib
The multi-center, randomized, double-blind, parallel-arm, placebo-controlled Phase 2/3 clinical study of opaganib for severe COVID-19 patients is planned to be conducted in Russia and additional European and other countries -- In parallel, a Phase 2a clinical study of opaganib for severe COVID-19 ...
View HTML